초록 ▼

Causative microorganisms of infectious diseases are detected and/or identified rapidly and with high sensitivity by taking phagocytes from clinical specimens containing active phagocytes, immobilizing the phagocytes so taken, treating the phagocytes to improve cell membrane permeabilities thereof, f

Causative microorganisms of infectious diseases are detected and/or identified rapidly and with high sensitivity by taking phagocytes from clinical specimens containing active phagocytes, immobilizing the phagocytes so taken, treating the phagocytes to improve cell membrane permeabilities thereof, further treating the phagocytes to bare DNA in the causative microorganisms which might exist in the phagocytes, and detecting the causative microorganisms with DNA probes which can hybridize with such DNA under stringent conditions.

대표청구항 ▼

The invention claimed is: 1. A method for detecting and/or identifying microorganisms causative of infectious diseases, comprising the steps of: (a) taking phagocytes from a clinical specimen and adjusting cell density of the phagocytes to between 5×106 cells/ml and 1×108 cells/ml; (b) im

The invention claimed is: 1. A method for detecting and/or identifying microorganisms causative of infectious diseases, comprising the steps of: (a) taking phagocytes from a clinical specimen and adjusting cell density of the phagocytes to between 5×106 cells/ml and 1×108 cells/ml; (b) immobilizing the phagocytes onto a solid support; (c) treating the phagocytes with lytic enzyme under the presence of protease inhibitor to increase phagocyte cell membrane permeability and bare DNA in the phagocytes; (d) in situ hybridizing the bared DNA with at least one DNA probe which can hybridize with DNA of at least one microorganism causative of an infectious disease under conditions wherein the hybridization of the at least one DNA probe is specific to the DNA of the at least one microorganism causative of an infectious disease; and (e) detecting and/or identifying the at least one microorganism causative of an infectious disease by detecting hybridization the of at least one probe to the bared DNA. 2. The method according to claim 1, wherein the lytic enzyme in step (c) is selected from the group consisting of Lysostaphin in a titer of from 1 Unit/ml to 1,000 Units/ml; Lysozyme in a titer of from 1,000 Units/ml to 1,000,000 Units/ml; N-acetylmuramidase in a titer of from 10 Units/ml to 10,000 Units/ml; Zymolase in a titer of from 50 Units/ml to 500 Units/ml, and a combination of any of the foregoing. 3. The method according to claim 1, wherein step (c) is performed under a temperature of about 26° C. to about 59° C. for about 15 to about 120 minutes. 4. The method according to claim 1, wherein the protease inhibitor in said step (c) is phenylmethylsulfonyl fluoride (PMSF). 5. The method according to claim 4, wherein the PMSF is employed at a concentration of about 10 μmol/l to about 10 mmol/l. 6. The method according to claim 1, wherein the protease inhibitor in said step (c) is dissolved into dimethylsulfoxide (DMSO). 7. The method according to claim 6, wherein the DMSO is in a concentration of less than about 5% by volume. 8. The method according to claim 1, wherein step (d) is performed at a temperature of about 25° C. to about 50° C. for about 30 to about 900 minutes. 9. The method according to claim 1, wherein the solid support in step (b) is a slide coated with 3-aminopropyl triethoxysilane. 10. The method according to claim 1, wherein step (e) comprises detecting signals resulting from hybridization, wherein pigment is employed to distinguish between said signals and cells. 11. The method according to claim 1, wherein the clinical specimen is blood. 12. The method according to claim 1, wherein length of the at least one DNA probe is from about 350 bases to about 600 bases. 13. The method according to claim 1, wherein concentration of the at least one DNA probe is from about 0.1 ng/μl to about 2.2 ng/μl. 14. The method of claim 1, wherein the in situ hybridizing of step (d) is performed in the presence of a surfactant. 15. The method according to claim 14, wherein the surfactant is sodium dodecyl sulfate (SDS). 16. A method for diagnosing sepsis or bacteremia, comprising: (a) taking phagocytes from a clinical specimen and adjusting cell density of the phagocytes to between 5×106 cells/ml and 1×108 cells/ml; (b) immobilizing the phagocytes onto a solid support; (c) treating the phagocytes with lytic enzyme under the presence of protease inhibitor to increase phagocyte cell membrane permeability and bare DNA in the phagocytes; (d) in situ hybridizing the bared DNA with at least one DNA probe which can hybridize with DNA of at least one microorganism causative of sepsis or bacteremia under conditions wherein the hybridization of the at least one DNA probe is specific to DNA of the at least one microorganism causative of sepsis or bacteremia; and (e) diagnosing sepsis or bacteremia by detecting hybridization of at least one probe to the bared DNA. 17. The method of claim 16, wherein the in situ hybridizing of step (d) is performed in the presence of a surfactant.